CA2189990A1 - Compositions et traitement de la sclerose en plaques - Google Patents

Compositions et traitement de la sclerose en plaques

Info

Publication number
CA2189990A1
CA2189990A1 CA002189990A CA2189990A CA2189990A1 CA 2189990 A1 CA2189990 A1 CA 2189990A1 CA 002189990 A CA002189990 A CA 002189990A CA 2189990 A CA2189990 A CA 2189990A CA 2189990 A1 CA2189990 A1 CA 2189990A1
Authority
CA
Canada
Prior art keywords
peptide
mbp
amino acid
acid residues
human mbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002189990A
Other languages
English (en)
Inventor
Di-Hwei Hsu
Dawn Smilek
Jia Dong Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2189990A1 publication Critical patent/CA2189990A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement de la sclérose en plaques. Lesdites compositions comprennent au moins un peptide ou un peptide modifié de la protéine basale de myéline (MBP) qui comprend au moins un déterminant antigénique de lymphocyte T, et de l'interféron-.beta. dans un véhicule pharmaceutiquement acceptable pour l'administration par voie orale, sous-cutanée ou intraveineuse. Les procédés selon l'invention consistent à traiter des individus souffrant de sclérose en plaques ou sujets à la sclérose en plaques par l'administration d'une dose thérapeutiquement efficace d'une composition de l'invention ou par l'administration, dans le cadre d'un schéma thérapeutique, d'une composition comprenant au moins un peptide ou un peptide modifié de la protéine basale de myéline, qui comprend au moins un déterminant antigénique de lymphocyte T, ainsi que de l'interféron .beta..
CA002189990A 1994-05-10 1995-05-04 Compositions et traitement de la sclerose en plaques Abandoned CA2189990A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US32822494A 1994-10-25 1994-10-25
US08/328,224 1994-10-25
US08/241,246 1994-10-25
PCT/US1995/005605 WO1995030435A2 (fr) 1994-05-10 1995-05-04 Compositions et traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
CA2189990A1 true CA2189990A1 (fr) 1995-11-16

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002189990A Abandoned CA2189990A1 (fr) 1994-05-10 1995-05-04 Compositions et traitement de la sclerose en plaques

Country Status (11)

Country Link
EP (1) EP0758902A1 (fr)
JP (1) JPH10500109A (fr)
AU (1) AU2470595A (fr)
CA (1) CA2189990A1 (fr)
CZ (1) CZ329596A3 (fr)
HU (1) HUT76099A (fr)
IL (1) IL113661A0 (fr)
PL (1) PL317197A1 (fr)
SI (1) SI9520059A (fr)
SK (1) SK145896A3 (fr)
WO (1) WO1995030435A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9520118A (sl) * 1994-10-25 1998-08-31 Immulogic Pharmaceutical Corporation Sestavki in zdravljenje multiple skleroze
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
EP0922057A1 (fr) * 1996-03-28 1999-06-16 Immulogic Pharmaceutical Corporation Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
HU229377B1 (hu) * 2000-08-21 2013-11-28 Apitope Technology Bristol Ltd Tolerogén humán peptidek
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
NZ546807A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9306272A (pt) * 1992-04-09 1998-06-23 Autoimmune Inc Peptídeo e composiçao farmacêutica
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease

Also Published As

Publication number Publication date
AU2470595A (en) 1995-11-29
IL113661A0 (en) 1995-08-31
PL317197A1 (en) 1997-03-17
SI9520059A (en) 1997-08-31
EP0758902A1 (fr) 1997-02-26
WO1995030435A2 (fr) 1995-11-16
HU9603116D0 (en) 1997-01-28
HUT76099A (en) 1997-06-30
SK145896A3 (en) 1997-05-07
JPH10500109A (ja) 1998-01-06
CZ329596A3 (en) 1997-05-14
WO1995030435A3 (fr) 1995-12-07

Similar Documents

Publication Publication Date Title
ES2303361T3 (es) Conjugados de interferon-alfa-polimero con actividad biologica potenciada y procedimientos de preparacion de los mismos.
CA2189990A1 (fr) Compositions et traitement de la sclerose en plaques
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
CN105073110B (zh) 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物
JPH05508662A (ja) 自己抗体の経口投与による自己免疫性疾患の治療
US8454947B1 (en) PEG-interferon lambda 1 conjugates
CA2487038A1 (fr) Polytherapies a base de vitamine b12 et d'agents therapeutiques destinees au traitement des affections virales, proliferantes et inflammatoires
US10363306B2 (en) Cytokines and neuroantigens for treatment of immune disorders
FR2773156A1 (fr) Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
ES2201137T3 (es) Analogos del peptido p277 y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de la diabetes.
TW202043255A (zh) 具增進氧化還原酶基序之免疫原肽
JPH05501866A (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
EP2748328A1 (fr) Conjugués lambda 1 d'interféron peg
US6265374B1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
JPH07504662A (ja) 免疫無防備状態の宿主における治療用途のための免疫促進剤
AU684713B2 (en) Peptide T and related peptides in the treatment of inflammatory bowel disease
US20230181638A1 (en) Immunogenic peptides with new oxidoreductase motifs
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
RU2130317C1 (ru) Линейные или циклические пептиды, их применение, способ лечения
WO2019099368A1 (fr) Compositions et méthodes pour traiter ou prévenir le diabète de type 1 en utilisant un modificateur de la réponse biologique en association avec une ou plusieurs thérapies de type régénération ou remplacement d'îlots de langerhans ou de cellules bêta

Legal Events

Date Code Title Description
FZDE Discontinued